FedRAMP High Win And Insurance Tie-Up Might Change The Case For Investing In Qualys (QLYS)
Qualys, Inc. QLYS | 0.00 |
- Earlier this month, Qualys and Converge launched an automated cyber insurance reporting offering powered by the Qualys Converge Connect Insurance Report, while Qualys also secured FedRAMP High Authorization for its TotalCloud CNAPP solution, expanding its reach with U.S. federal agencies and highly regulated industries.
- Together, these moves tie Qualys’ risk analytics directly to both cloud-compliant government workloads and cyber insurance underwriting, potentially reshaping how customers measure, report, and financially incentivize better security hygiene.
- We’ll now examine how FedRAMP High-certified TotalCloud, combined with automated cyber insurance reporting, may influence Qualys’ longer-term investment narrative.
AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Qualys Investment Narrative Recap
To stay a shareholder in Qualys, you need to believe its risk analytics platform can remain central to pre breach security, even as competition and customer consolidation pressures intensify. Near term, the key catalyst is broader adoption of its cloud and AI driven remediation tools, while the biggest risk is slower new business growth and share loss to larger platforms. The latest FedRAMP High win and cyber insurance tie up support the catalyst but do not remove that risk.
The most relevant update here is Q1 2026 results and the raised full year outlook. Revenue grew to US$175.64 million with net income of US$50.64 million, and management nudged 2026 revenue guidance up to US$721.0 million to US$727.0 million and GAAP EPS to US$5.40 to US$5.61. That combination of execution and slightly higher guidance gives more context for how FedRAMP High TotalCloud and the Converge insurance reporting partnership might influence the story from here.
Yet beneath the improved outlook, the risk that larger platforms could sideline Qualys’ tools is something investors should be aware of if...
Qualys’ narrative projects $841.9 million revenue and $222.1 million earnings by 2029.
Uncover how Qualys' forecasts yield a $107.39 fair value, a 19% upside to its current price.
Exploring Other Perspectives
By contrast, the most pessimistic analysts see a tougher road, with revenue only reaching about US$819.7 million and earnings around US$203.5 million by 2029, so it is worth weighing those more cautious assumptions against the new FedRAMP and insurance reporting developments as you consider how your own view might differ.
Explore 4 other fair value estimates on Qualys - why the stock might be worth as much as 39% more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Qualys research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Qualys research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Qualys' overall financial health at a glance.
Contemplating Other Strategies?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
